ADMA Biologics, Inc.
ADMA
$17.02
$0.110.65%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 63.39% | 58.69% | 55.68% | 67.59% | 79.56% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 63.39% | 58.69% | 55.68% | 67.59% | 79.56% |
| Cost of Revenue | 20.49% | 17.79% | 28.30% | 42.47% | 53.25% |
| Gross Profit | 160.03% | 167.02% | 131.81% | 152.21% | 192.82% |
| SG&A Expenses | 5.98% | -4.37% | -7.66% | -9.98% | -2.75% |
| Depreciation & Amortization | -23.06% | -1.93% | 3.27% | 1.34% | 0.04% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.01% | 9.58% | 15.27% | 22.30% | 31.63% |
| Operating Income | 8,470.92% | 603.81% | 274.53% | 154.95% | 102.88% |
| Income Before Tax | 421.36% | 197.22% | 93.60% | 57.15% | 67.54% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 398.48% | 186.34% | 92.36% | 57.15% | 67.54% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 398.48% | 186.34% | 92.36% | 57.15% | 67.54% |
| EBIT | 8,470.92% | 603.81% | 274.53% | 154.95% | 102.88% |
| EBITDA | 1,195.73% | 1,156.99% | 395.78% | 192.88% | 123.87% |
| EPS Basic | 368.92% | 176.25% | 92.61% | 62.31% | 70.45% |
| Normalized Basic EPS | 496.60% | 245.21% | 142.57% | 96.64% | 67.39% |
| EPS Diluted | 349.91% | 168.72% | 91.06% | 61.61% | 69.88% |
| Normalized Diluted EPS | 481.27% | 240.54% | 141.35% | 96.53% | 67.29% |
| Average Basic Shares Outstanding | 5.63% | 8.14% | 10.44% | 13.19% | 13.42% |
| Average Diluted Shares Outstanding | 7.73% | 11.20% | 12.40% | 14.26% | 14.53% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
